Acquisition Leverage Eli Lilly's acquisition places Curevo within a global commercial network, offering immediate avenues to extend shingles vaccine reach through Lilly's sales channels and market access teams. This creates opportunities for co development, licensing, or distribution partnerships that can accelerate adoption of CRV-101.

Phase Progress Potential Positive phase two data and ongoing clinical progress position Curevo to engage payers, providers, and distribution partners early in the commercialization journey. Prioritize building payer value dossiers, key opinion leader engagement, and pilot access programs to speed evidence generation for formulary decisions.

Differentiation Advantage Curevo's adjuvanted subunit vaccine aims for noninferior efficacy with improved reactogenicity relative to the current standard, a differentiator that can drive formulary wins and higher patient acceptance. Tailor sales messaging to clinicians and health systems emphasizing tolerability and vaccination uptake benefits.

Manufacturing Partnerships A lean team suggests a need for external manufacturing partners to scale supply as development advances. Target contract manufacturing organizations and logistics partners for fill finish and distribution to support trials and potential commercialization, as well as risk sharing.

Leadership Credibility Recent funding and influential leadership appointments, including a high profile board chair and substantial funding, strengthen Curevo's profile for strategic partnerships, licensing talks, and co development opportunities with larger vaccine players.